Incyte (INCY) Net Cash Flow Growth (1y) (2011 - 2026)
Incyte (INCY) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | 43.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.81% |
| Dec 31, 2025 | 69.31% |
| Sep 30, 2025 | 57.58% |
| Jun 30, 2025 | 100.62% |
| Mar 31, 2025 | 90.93% |
| Dec 31, 2024 | 6,016.68% |
| Sep 30, 2024 | 239.22% |
| Jun 30, 2024 | -856.15% |
| Mar 31, 2024 | 202.41% |
| Dec 31, 2023 | -102.47% |
| Sep 30, 2023 | -63.18% |
| Jun 30, 2023 | 75.68% |
| Mar 31, 2023 | -165.37% |
| Dec 31, 2022 | 346.36% |
| Sep 30, 2022 | 24.96% |
| Jun 30, 2022 | 39.30% |
| Mar 31, 2022 | 25.07% |
| Dec 31, 2021 | 254.18% |
| Sep 30, 2021 | 20.41% |
| Jun 30, 2021 | -54.88% |